Back to News
Market Impact: 0.2
MIRA Pharmaceuticals Consensus Price Target Increased by 16.67% to $3.57
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
The aggregate one-year analyst price target for MIRA Pharmaceuticals was raised 16.67% to $3.57 per share from $3.06 on January 11, 2026. The revision indicates improved analyst expectations for the biotech company, though the article provides no underlying earnings, clinical, or operational catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
MIRA0.40
More News
- Trump teases more inflationary money for voters ahead of midterm elections, now promising $90 payments after touting $500 and $5,000 checks
- Goldman Sachs says buy these stocks now, ahead of their earnings
- AI will create more jobs than it kills, McKinsey says. The catch: 11 million Americans may need new careers
- Gaza voters want jobs and security as Palestinian elections approach
- Spotify billionaire’s body scan startup has come to America
- I’m an obesity expert and can’t wait for the compounding craze to stop